Endothelin-1 and nitric oxide levels are related to cardiovascular risk factors but are not modified by estradiol replacement in healthy postmenopausal women. A cross-sectional and a randomized cross-over study

Maturitas

Volumn 44, Issue 2, 2003, Pages 117-124

  Cagnacci, Angelo ^a,d   Tarquini, Roberto ^b   Perfetto, Federico ^b   Arangino, Serenella ^a   Zanni, Anna Lisa ^a   Cagnacci, Paolo ^c   Facchinetti, Fabio ^a   Volpe, Annibale ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Cardiovascular risk factors; Endothelin; Menopause; Nitric oxide

Indexed keywords

ENDOTHELIN 1; ESTRADIOL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PROTEIN C;

ADULT; AGE; ARTICLE; BLOOD CLOTTING; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE METABOLISM; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; LIPID METABOLISM; MULTIVARIATE ANALYSIS; NORMAL HUMAN; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, CUTANEOUS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; CROSS-SECTIONAL STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIN-1; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INSULIN; MIDDLE AGED; NITRIC OXIDE; POSTMENOPAUSE; PROTEIN C; TREATMENT OUTCOME;

EID: 12244304231     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(02)00319-5     Document Type: Article

References (40)

1. Vane J.R., Anggard E.E., Botting R.M. Regulatory functions of the vascular endothelium. Review article. N. Engl. J. Med. 323:1990;27-36.
2. Mathew V., Hasdai D., Lermen A. A role of endothelin in coronary atherosclerosis. Mayo Clin. Proc. 71:1996;769-777.
3. Schmitz-Spanke S., Schipke J.D. Potential role of endothelin-1 and endothelin antagonists in cardiovascular diseases. Bas. Res. Cardiol. 95:2000;290-298.
4. Luscher T.F., Dohi Y., Tanner F.C., Boulanger C. Endothelium-dependent control of vascular tone: effect of age, hypertension and lipids. Bas. Res. Cardiol. 86:(Suppl 2):1991;143-158.
5. Sarman B., Farkas K., Toth M., Somogyi A., Tulassay Z. Circulating plasma endothelin-1, plasma lipids and complications in Type 1 diabetes mellitus. Diab. Nutr. Metab. 13:2000;142-148.
6. Piatti P.M., Monti L.D., Galli L., et al. Relationship between endothelin-1 concentration and metabolic alterations typical of the insulin resistance syndrome. Metabolism. 49:2000;748-752.
7. Mangiafico R.A., Malatino L.S., Santonocito M., Spada R.S., Polizzi G., Tamburino G. Raised plasma endothelin-1 concentrations in patients with primary hypercholesterolemia without evidence of atherosclerosis. Int. Angiol. 15:1996;240-244.
8. Luscher T.F., Yang Z., Tschudi M., et al. Interaction between endothelin-1 and endothelium derived relaxing factor in human arteries and veins. Circ. Res. 66:1990;1088-1094.
9. Boulanger C., Luscher T.F. Release endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J. Clin. Invest. 85:1990;587-590.
10. Ignarro L.J. Biosynthesis and metabolism of endothelium derived nitric oxide. Ann. Rev. Pharmacol. Tossicol. 30:1990;535-560.
11. Moncada S., Higgs E.A. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329:1993;2003-2012.
12. Schachinger V., Britten M.B., Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 101:2000;1899-1906.
13. Gokce N., Keaney J.F., Hunter L.M., Watkins M.T., Menzoian J.O., Vita J.A. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function. A prospective study. Circulation. 105:2002;1567-1572.
14. Ylikorkala O., Orpana A., Puolakka J., Pyorala T., Viinikka L. Postmenopausal hormonal replacement decrease plasma levels of endothelin-1. J. Clin. Endocrinol. Metab. 80:1995;3384-3387.
15. Wilcoxon J.G., Hatch I.E., Gentzschen E., Stanczyk F.Z., Lobo R. Endothelin levels decrease after oral and non oral estrogen in postmenopausal women with increased cardiovascular risk factors. Fertil. Steril. 67:1997;273-277.
16. Best P.J.M., Berger P.B., Miller V.M., Lerman A. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann. Inter. Med. 128:1998;285-288.
17. Van Baal W.M., Kenemans P., Ermeis J.J., et al. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. Fertil. Steril. 71:1999;663-670.
18. Imthurn B., Rosselli M., Jager A.W., Keller P.K., Dubey R.K. Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J. Clin. Endocrinol. Metab. 82:1997;388-394.
19. Cicinelli E., Ignarro L.J., Lograno M., Matteo G., Falco N., Schonauer L.M. Acute effects of transdermal estradiol administration on plasma levels of nitric oxide in postmenopausal women. Fertil. Steril. 67:1997;63-66.
20. Cicinelli E., Ignarro L.J., Matteo M.G., Galantino P., Schonauer L.M., Falco N. Effects of estrogen replacement on plasma levels of nitric oxide in postmenopausal women. Am. J. Obstet. Gynecol. 180:1999;334-339.
21. Lieberman E.H., Gerhard M.D., Uehata A., et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann. Inter. Med. 121:1994;936-941.
22. Gerhard M., Walsh B.W., Tawakol A., et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation. 98:1998;1158-1163.
23. Ylikorkala O., Cacciatore B., Paakkari I., Tikkanen M.J., Viinikka L., Toivonen J. The long-term effects of oral and transdermal postmenopausal therapy on nitric oxide, endothelin-1, prostacyclin and thromboxane. Fertil. Steril. 69:1998;883-888.
24. Van Baal W.M., Emeis J.J., Kenemans P., et al. Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules. Eur. J. Clin. Invest. 29:1999;913-921.
25. Anwaar I., Rendell M., Gottsater A., Lindgarde F., Hulthen U.L., Mattiasson I. Hormone replacement therapy in healthy postmenopausal women. Effects on intraplatelet cyclic guanosine monophosphate plasma endothelin-1 and neopterin. J. Int. Med. 247:2000;463-470.
26. Saltevo J., Puolakka J., Yikorkala O. Plasma endothelin in postmenopausal women with type 2 diabetes mellitus and metabolic syndrome: a comparison of oral combined and transdermal estrogen-only replacement therapy. Diab. Obes. Metab. 2:2000;293-298.
27. Cagnacci A., Modena M.G., Malmusi S., Muia N., Volpe A. Effect of prolonged administration of transdermal estradiol on flow-mediated endothelium-dependent and endothelium-independent vasodilation in healthy postmenopausal women. Am. J. Cardiol. 84:1999;367-370.
28. Vehkavaara S., Hakala-Ala-Pietila T., Virkamaki A., et al. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation. 102:2000;2687-2693.
29. Cagnacci A., Rovati L., Zanni A.L., Malmusi S., Facchinetti F., Volpe A. Physiological doses of estradiol decrease nocturnal blood pressure in normotensive postmenopausal women. Am. J. Physiol. 276:1999;1355-1360.
30. Rich-Edwards J., Manson J.E., Hennekens C.H., Buring J.E. The primary prevention of coronary heart disease. N. Engl. J. Med. 332:1995;1758-1766.
31. Achmad T.H., Winterscheidt A., Lindemann C., Rao G.S. Oxidized low density lipoprotein acts on endothelial cells in culture to enhance endothelin secretion and monocyte migration. Methods Finding Exp. Clin. Pharmacol. 19:1997;153-159.
32. Goode G.K., Miller J.P., Heagerty A.M. Hyperlipidaemia, hypertension, and coronary heart disease. Lancet. 345:1995;362-364.
33. Anderson E.A., Hoffman R.P., Balon T.W., Sinkey C.A., Mark A.L. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J. Clin. Invest. 87:1991;2246-2252.
34. Surdacki A., Nowicki M., Sandmann J., et al. Effects of acute euglycemic hyperinsulinemia on urinary nitrite/nitrate and plasma endothelin-1 levels in men with essential hypertension and normotensive controls. Metabolism. 48:1999;887-891.
35. Meade T.W., Stirling Y., Wilkes H., Mannucci P.M. Effects of oral contraceptives and obesity on protein C antigen. Thromb. Haemost. 53:1985;198-199.
36. Meade T.W., Cooper J., Miller G.J., Howarth D.J., Stirling Y. Antithrombin III and arterial disease. Lancet. 338:1991;850-851.
37. Dschietzig T., Alexiou K., Laule M., et al. Stimulation of pulmonary big endothelin-1 by antithrombin III: a rationale for combined application of antithrombin III and endothelin antagonists in sepsis related acute respiratory distress syndrome? Crit. Care Med. 28:2000;2445-2449.
38. Wanececk M., Witzberg E., Rudehill A., Oldner A. The endothelin system in septic and endotoxin shock. Eur. J. Pharmacol. 401:2000;1-15.
39. Pietraszem M., Chabielska E., Azzadin A., Pawlak R., Buczko W. Effect of endothelin-1 on some hemostatic parameters in normotensive rats. Acta Physiol. Acad. Sci. Hung. 84:1996;329-330.
40. De Kreutzenberg S.V., Crepaldi C., Marchetto S., et al. Plasma free fatty acids and endothelium-dependent vasodilation: effect of chain-length and cyclooxygenase inhibition. J. Clin. Endocrinol. Metab. 85:2000;793-798.